Enovix (NASDAQ:ENVX) Price Target Cut to $2.50 by Analysts at Canaccord Genuity Group

Enovix (NASDAQ:ENVX – Get Free Report) had its target price cut by stock analysts at Canaccord Genuity Group to $2.50 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group‘s target price would suggest a potential upside of 76.80% from the company’s previous close.

ENVX has been the topic of a number of other reports. Bank of America reaffirmed a “neutral” rating and set a $4.00 price target on shares of Enovix in a research report on Monday, August 17th. Craig Hallum cut Enovix from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Enovix in a research note on Thursday, August 13th. Northland Securities set a $4.00 target price on Enovix in a research report on Tuesday, October 13th. Finally, Oppenheimer cut Enovix from an “outperform” rating to a “market perform” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.25.

View Our Latest Stock Report on ENVX

Enovix Stock Down 11.6%

Shares of NASDAQ ENVX traded down $0.19 during mid-day trading on Monday, reaching $1.41. 13,021,897 shares of the company’s stock traded hands, compared to its average volume of 7,255,429. The stock has a market cap of $310.30 million, a P/E ratio of -1.94 and a beta of 2.34. The business has a 50-day simple moving average of $2.23 and a 200 day simple moving average of $3.93. Enovix has a 1-year low of $1.28 and a 1-year high of $9.19. The company has a debt-to-equity ratio of 2.46, a current ratio of 9.71 and a quick ratio of 9.37.

Enovix (NASDAQ:ENVX – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. Enovix had a negative net margin of 406.54% and a negative return on equity of 67.80%. The company had revenue of $11.04 million for the quarter. On average, analysts expect that Enovix will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Sax Wealth Advisors LLC bought a new position in shares of Enovix in the third quarter worth approximately $29,000. Sequoia Financial Advisors LLC bought a new stake in Enovix during the second quarter valued at approximately $61,000. Gateway Wealth Partners LLC purchased a new position in Enovix in the 1st quarter worth approximately $68,000. Wealthfront Advisers LLC increased its holdings in shares of Enovix by 27.8% in the 1st quarter. Wealthfront Advisers LLC now owns 13,800 shares of the company’s stock worth $71,000 after buying an additional 3,001 shares during the last quarter. Finally, Allworth Financial LP bought a new position in shares of Enovix in the 2nd quarter worth $71,000. 50.92% of the stock is currently owned by hedge funds and other institutional investors.

About Enovix

(Get Free Report)

Enovix Corporation develops lithium-ion batteries using a silicon-based anode and a proprietary three-dimensional cell architecture. Its design is intended to increase energy density while addressing safety and performance requirements in compact devices. The company’s batteries are designed for applications including smartphones, wearable devices, laptops, augmented- and virtual-reality products, and other portable electronics. Enovix also targets markets such as defense and industrial technology.

Featured Articles

Analyst Recommendations for Enovix (NASDAQ:ENVX)

Receive News & Ratings for Enovix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovix and related companies with MarketBeat.com's FREE daily email newsletter.